University of Hawai‘i at Manoa Homepage

Faculty

Paul T. Morris, MD, FACS, FCCP

Paul T. Morris, MD
  • Clinical Member
    Translational and Clinical Research
    University of Hawaii Cancer Center
  • Member
    Search Committee
    Translational and Clinical Research
    University of Hawaii Cancer Center
  • Member
    Clinical Member
    Hawaii Cancer Consortium Executive Committee
  • Academic Appointments

  • Assistant Clinical Professor
    University of Hawaii Cancer Center
    University of Hawaii at Manoa
  • Assistant Professor of Surgery
    John A. Burns School of Medicine
    University of Hawaii at Manoa

Degrees

  • MD
    Georgetown University
  • Chief Resident and Junior Faculty Associate
    Thoracic & Cardiovascular Surgery
    M.D. Anderson Cancer Center
    University of Texas
    Houston, TX
  • Cardio-Thoracic Surgery Resident
    Texas Heart Institute
    Houston, TX
  • Clinical Associate
    Mount Sinai Medical Center
    New York, NY
  • General Surgery Resident
    Mount Sinai Mecial Center
    New York, NY

Research Focus

Dr. Morris has been Chief of Surgery at The Queen's Medical Center since 2009. He has had a long-time interest in optimizing ways to prevent and treat cancer. He has been a clinical faculty member of the University of Hawaii Cancer Center since 1995, has served as President of the Hawaii Society of Clinical Oncology, and has chaired the Cancer Committee and Tumor Board conferences at The Queen's Medical Center for many years He is the Co-Principal Investigator of the current Hawaii Minority/Underserved NCI Community Oncology Research Program (NCORP) grant that focuses on minority and medically underserved populations in Hawaii. His team at The Queen's Medical Center works closely with the Cancer Center and its consortium partners to expand clinical trials and foster translational research that will benefit all cancer patients in the State.

Selected Publications

  • Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M. (2017). BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature, 546:549-553. doi: 10.1038/nature22798.
  • Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, Salim Saad-Jube Z, Napolitano A, Pagano I, Negi VS, Bianchi ME, Morris P, Pass HI, Gaudino G, Carbone M, Yang H. (2017). HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget, 8:22649-22661.
  • Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, Gazdar AF, Pass HI, Yang H. (2012). Malignant mesothelioma: Facts, myths and hypotheses. J Cell Physiol, 227: 44-58, Jan. PMCID: PMC3143206.
  • Nasu M, Carbone M, Gaudino G, Ly BH, Bertino P, Shimizu D, Morris P, Pass HI, Yang H. (2011). Ranpirnase interferes with NF-κB pathway and MMP9 activity, inhibiting Malignant Mesothelioma cell invasiveness and xenografts growth. Genes & Cancer, 2:576-84.
  • Zhang L, Strianese O, Gaudino G, Morris P, Pass HI, Yang H, Nerurkar VR, Bocchetta M, Carbone M. (2010). Tissue tropism of SV40 transformation of human cells: role of the viral regulatory region and of cellular oncogenes. Genes and Cancer, 1:1008-1020, PMCID: PMC3092263.
  • Zhang L, Qi F, Gaudino G, Strianese O, Yang H, Morris P, Pass HI, Nerurkar VR, Bocchetta M, Carbone M; (2010). Submitted 21-May-2010; revised 21-Nov-2010; accepted 29-Nov-2010.

Publication list via PubMed

Active Grants

  • P. Morris, Co-Investigator
    Pathogenesis of Malignant Mesothelioma
    February 2010 to Present
  • P. Morris, C-PI for Cancer Care Delivery Research
    NCI
    5UG1CA189804-03
    National Cancer Institute Community Oncology Research Program
    The NCORP overall goal is to bring cancer clinical trials and cancer care delivery research (CCDR) to people in their own communities, thereby generating a broadly applicable evidence base that contributes to improved patient outcomes and a reduction in cancer disparities.
    03/01/14-07/31/19

  • P. Morris, Principal Investigator
    "National Cancer Institute Community Cancer Center Program, Queens Medical Center"
    Primary responsibilities: fiscal oversight of a 3.3 million dollar contract from the NCCCP to oversee the implementation of all aspects of a community cancer center program which includes merging private practice physicians into an outpatient hospital setting. A pioneering effort that is being accomplished through design and vision by creating pathways to ensure a successful transition with regard to insurance reimbursement and compliance issues. Acting as liaison during the negotiation of the Conditions of Participation (CoPs), in which the roles of QMC and providers were clarified to fit this new setting. A major goal is to establish a multi-disciplinary care clinic (MDC,) utilizing National Cancer Institute standards through the recruitment of private practice oncology and primary care physicians, as well as QMC co-management and employed physicians, providing each new patient multiple physician consultations, from specialists in medical oncology, radiation oncology and surgical subspecialties. Since April 2010, fifty three physicians have aligned themselves with the MDCs by signing CoPs. Instituted the use of Dragon Dictate in the Cancer Center, to advance EHR and reduce transcription costs from the influx of physician activity in the Cancer Center. Also accountable for collecting data for submission to the NCCCP for their use in determining Pay for Performance and Accountable Care Organization policies for oncology on a national level.
    2010-present.